# InnoCare Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innocare-pharma

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.innocarepharma.com
- Total disclosed funding: $55M
- Latest round: Series A (Feb 8, 2018)
- Investors on record: 3

## About

InnoCare Pharma, Ltd. is a biopharmaceutical company focused on developing and commercializing innovative therapies for oncology and autoimmune diseases, aiming to address significant unmet medical needs.Founded in 2013 and headquartered in Beijing, China, InnoCare Pharma, Ltd. specializes in biopharmaceuticals. The company has undergone notable growth, successfully raising HKD 2.24 billion in its most recent PIPE funding round on March 16, 2020, with total funds raised amounting to HKD 125.000 mn. The company is led by CEO Jisong Cui, who has an extensive background in the biopharmaceutical sector.InnoCare specializes in the development and commercialization of innovative biopharmaceutical products aimed at addressing significant unmet medical needs within the oncology and autoimmune disease sectors. Their core product offerings include targeted therapies designed to specifically inhibit disease progression and improve patient outcomes. These products are particularly geared towards treating conditions such as cancer and autoimmune disorders, with a focus on enhancing the quality of life for patients. InnoCare's products have been launched in various international markets, including but not limited to China, the United States, and several European countries, catering to a diverse client base that includes healthcare providers, hospitals, and specialty clinics.InnoCare generated revenue of HKD 161,671,195.80 in the most recent year, 2021, with an EBITDA of HKD 2,625,950.60. Revenue is primarily derived through the sale of biopharmaceutical products to healthcare institutions and strategic partnerships, facilitating a wider market reach. The company's flagship products, characterized by proprietary formulations, command premium pricing, contributing significantly to its operational sustainability.InnoCare Pharma, Ltd. plans to leverage its recent PIPE funding of HKD 2.24 billion to further develop and launch new biopharmaceutical products targeting oncology and autoimmune conditions. The company aims to expand its market presence in regions such as North America and Europe by 2023. This strategic growth is expected to enhance its product offerings and fulfill growing healthcare demands.

## Funding rounds

- Series A, Feb 8, 2018, $55M — Vivo Capital, CCB Private Equity Investment Management
- Angel, Oct 27, 2014 — Oriza Holdings

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- CCB Private Equity Investment Management (https://capitalatlas.ai/funds/ccb-private-equity-investment-management) — Series A